Olwen Hahn to Trastuzumab
This is a "connection" page, showing publications Olwen Hahn has written about Trastuzumab.
Connection Strength
0.245
-
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMBÂ trial). Eur J Cancer. 2021 08; 153:223-233.
Score: 0.197
-
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020 12 10; 38(35):4184-4193.
Score: 0.047